Drug Trial Radar · NCT07221474
A Study of Intismeran Autogene (V940)/Placebo + Pembrolizumab and Chemotherapy in Metastatic Squamous Non-Small Cell Lung Cancer (V940-013)
Last checked: Nov 20, 2026Latest source record: Nov 12, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Dec 12, 2025
Primary completion
Jul 2, 2029
Study completion May 6, 2031
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- Collaborators
- ModernaTX, Inc.
- First posted
- Oct 28, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Researchers want to know if intismeran autogene (the study treatment) given with pembrolizumab and chemotherapy can treat metastatic treatment-naive squamous non-small cell lung cancer (NSCLC). Intismeran autogene is designed to help a person's immune system attack their specific cancer. The goal of this study is to learn if people who receive intismeran autogene with pembrolizumab and chemotherapy live longer overall and without the cancer growing or spreading compared to people who receive placebo with pembrolizumab and chemotherapy. A placebo looks like the study treatment but has no study treatment in it. Using a placebo helps researchers better understand the effects of the study treatment.
Conditions
- Squamous Non-small Cell Lung Cancer
Interventions
Intismeran AutogeneBiological
1 mg Intramuscular (IM) Injection
PembrolizumabBiological
200 mg IV Infusion
CarboplatinDrug
Area Under the Curve (AUC) either 6 or 5 (mg/mL/min) IV Infusion
PaclitaxelDrug
200 or 175 mg/m\^2 IV Infusion
Nab-paclitaxelDrug
100 mg/m\^2 IV Infusion
PlaceboOther
Placebo matched to Intismeran Autogene IM injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression Free Survival (PFS)Time frame: Up to ~32 months
- Overall Survival (OS)Time frame: Up to ~42 months
Locations
56 sites in 11 countries. Site status is shown where the registry gives one.
Moffitt Cancer Center ( Site 0021)
Tampa, Florida · Recruiting
VA Ann Arbor Healthcare System ( Site 0019)
Ann Arbor, Michigan · Recruiting
Washington University School of Medicine ( Site 0024)
St Louis, Missouri · Recruiting
Valley Health Systems - Ridgewood Campus ( Site 0010)
Paramus, New Jersey · Recruiting
New York Oncology Hematology (NYOH) - Albany Medical Center ( Site 9001)
Albany, New York · Recruiting
Cleveland Clinic - Ohio ( Site 0016)
Cleveland, Ohio · Recruiting
Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0025)
Corvallis, Oregon · Recruiting
Tennessee Oncology, PLLC - Elliston Place Plaza Medical Oncology & Hematology ( Site 9000)
Nashville, Tennessee · Recruiting
Texas Oncology - Central/South Texas ( Site 8002)
Austin, Texas · Recruiting
Virginia Cancer Specialists ( Site 0003)
Fairfax, Virginia · Recruiting
Swedish Medical Center-Swedish Cancer Institute ( Site 0023)
Seattle, Washington · Recruiting
Instituto Alexander Fleming ( Site 0201)
Ciudad Autonoma de Buenos Aires, Buenos Aires, Argentina · Recruiting
Hospital Italiano de Buenos Aires ( Site 0200)
Ciudad Autonoma de Buenos Aires., Buenos Aires, Argentina · Recruiting
Instituto de Investigaciones Clínicas Mar del Plata ( Site 0205)
Mar del Plata, Buenos Aires, Argentina · Recruiting
Clinica Adventista Belgrano ( Site 0206)
Caba., Buenos Aires F.D., Argentina · Recruiting
Fundacion Estudios Clinicos ( Site 0207)
Rosario, Santa Fe Province, Argentina · Recruiting
Sanatorio Parque ( Site 0203)
Rosario, Santa Fe Province, Argentina · Recruiting
Westmead Hospital ( Site 0400)
Westmead, New South Wales, Australia · Recruiting
Princess Alexandra Hospital ( Site 0403)
Woolloongabba, Queensland, Australia · Recruiting
One Clinical Research ( Site 0402)
Nedlands, Western Australia, Australia · Recruiting
Bradford Hill Norte ( Site 0308)
Antofagasta, Chile · Recruiting
Centro de Estudios Clínicos SAGA ( Site 0307)
Santiago, Region M. de Santiago, Chile · Recruiting
Fundación Arturo López Pérez ( Site 0300)
Santiago, Region M. de Santiago, Chile · Recruiting
Bradfordhill ( Site 0301)
Santiago, Region M. de Santiago, Chile · Recruiting
Centre Georges François Leclerc ( Site 0805)
Dijon, Cote-d Or, France · Recruiting
Institut de Cancérologie de l'Ouest ( Site 0801)
Angers, Pays de la Loire Region, France · Recruiting
CHU GABRIEL MONTPIED ( Site 0802)
Clermont-Ferrand, Puy-de-Dome, France · Recruiting
Ospedale San Raffaele-Oncologia Medica ( Site 1002)
Milan, Italy · Recruiting
Fondazione IRCCS Istituto Nazionale Dei Tumori ( Site 1000)
Milan, Italy · Recruiting
AO Santa Maria della Misericordia-Oncology Department ( Site 1005)
Perugia, Italy · Recruiting
Fondazione Policlinico Universitario Agostino Gemelli IRCCS - Università Cattolica del Sacro Cuore ( Site 1001)
Roma, Italy · Recruiting
Ospedale Santa Maria delle Croci-Dipartimento Oncoematologico ( Site 1004)
Ravenna, Emilia-Romagna, Italy · Recruiting
Wielkopolskie Centrum Pulmonologii i Torakochirurgii ( Site 1101)
Poznan, Greater Poland Voivodeship, Poland · Recruiting
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - Panstwowy Instytut Badawczy w Warszawie ( Site 1100)
Warsaw, Masovian Voivodeship, Poland · Recruiting
Wojewodzki Szpital im. Sw. Ojca Pio w Przemyslu ( Site 1102)
Przemyśl, Podkarpackie Voivodeship, Poland · Recruiting
Asan Medical Center ( Site 0503)
Seoul, South Korea · Recruiting
Samsung Medical Center ( Site 0502)
Seoul, South Korea · Recruiting
National Cancer Center ( Site 0504)
Goyang-si, Kyonggi-do, South Korea · Recruiting
Seoul National University Bundang Hospital ( Site 0500)
Seongnam-si, Kyonggi-do, South Korea · Recruiting
Chungbuk National University Hospital-Internal medicine ( Site 0501)
Cheongju-si, North Chungcheong, South Korea · Recruiting
Showing 40 of 56 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.